论文部分内容阅读
目的:探讨S100B蛋白在颅内肿瘤放疗治疗引起脑损伤患者血清中的作用及临床价值。方法:90例颅内肿瘤患者按放疗方案分为3组:普通放射治疗组(A组),普通放射治疗+三维适形放射治疗组(B组),三维适形或调强放射治疗组(C组),选择同期健康查体者30例为对照组。测定A、B、C3组患者放射治疗前、放射治疗中期、放射治疗后血清S100B蛋白水平和对照组血清S100B蛋白水平。结果:(1)治疗前肿瘤组患者血清S100B蛋白水平高于对照组,但差异无统计学意义(P<0.05)。3组患者治疗中和治疗后血清S100B水平与治疗前比较均显著升高(P<0.05),治疗后与治疗中比较显著升高(P<0.05)。治疗后S100B水平A组>B组>C组(P<0.05)。结论:颅内肿瘤患者血清S100B蛋白水平随着放疗阶段(剂量)不同而升高(P<0.05)。血清S100B蛋白水平对于颅内肿瘤放疗治疗引起脑损伤患者的早期诊断和预防具有重要的临床意义。
Objective: To investigate the role and clinical value of S100B protein in the treatment of brain injury caused by intracranial tumor radiotherapy. Methods Ninety patients with intracranial tumors were divided into three groups according to the radiotherapy regimen: general radiotherapy group (A group), general radiotherapy + 3D conformal radiotherapy group (B group), 3D conformal or IMRT group C group), select the same period 30 cases of physical examination for the control group. The levels of S100B protein in serum of patients in groups A, B and C3 before radiotherapy, in the middle of radiotherapy, after radiotherapy and in serum of control group were measured. Results: (1) The level of serum S100B in the tumor group before treatment was higher than that in the control group, but the difference was not statistically significant (P <0.05). Serum levels of S100B in the three groups were significantly higher than those before treatment (P <0.05), and significantly increased after treatment (P <0.05). After treatment S100B level A group> B group> C group (P <0.05). Conclusion: The serum level of S100B protein in patients with intracranial tumors increases with the stage of radiotherapy (dose) (P <0.05). Serum S100B protein level has important clinical significance for the early diagnosis and prevention of brain injury caused by intracranial tumor radiotherapy.